# Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease

> **NCT00137332** · PHASE2 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 90 (—)

## Conditions studied

- Arrhythmia

## Interventions

- **DRUG:** GAP-486 (ZP-123)
- **DRUG:** 0.9% Sodium Chloride, USP

## Key facts

- **NCT ID:** NCT00137332
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-11
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 90 (—)
- **Last updated:** 2007-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137332, "Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00137332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*